Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents
Authors:
- Fumio TsujiFTFumio Tsuji
- Masaaki MuraiMMMasaaki Murai
- Kenji OkiKOKenji Oki
- Iwao SekiISIwao Seki
- Kenji UedaKUKenji Ueda
- Hiroyuki InoueHIHiroyuki Inoue
- Lex NagelkerkenLNLex Nagelkerken
- Minoru SasanoMSMinoru Sasano
- Hiroyuki AonoHAHiroyuki Aono
- 1 February 2010
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 627 (1-3) , 332-339
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxinThe FASEB Journal, 2007
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosisNeurobiology of Disease, 2005
- Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapiesExpert Opinion on Investigational Drugs, 2004
- Biochemical pharmacology of the vanilloid receptor TRPV1European Journal of Biochemistry, 2004
- Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase‐2 induction by capsaicin and related analogs in macrophagesBritish Journal of Pharmacology, 2003
- Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin‐induced dural dilationBritish Journal of Pharmacology, 2003
- The Vanilloid Receptor: A Molecular Gateway to the Pain PathwayAnnual Review of Neuroscience, 2001
- The capsaicin receptor: a heat-activated ion channel in the pain pathwayNature, 1997
- Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteinsEuropean Journal of Immunology, 1994